We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
Read MoreHide Full Article
Arcturus Therapeutics (ARCT - Free Report) shares ended the last trading session 7.7% higher at $23.16. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.3% gain over the past four weeks.
The sudden uptick can be attributed to a positive investor mindset regarding the potential of ARCT’s wholly-owned pipeline comprising two mRNA therapeutic candidates, ARCT-810 and ARCT-032, undergoing mid-stage development for ornithine transcarbamylase deficiency and cystic fibrosis, respectively. Arcturus, in partnership with renowned vaccine company CSL Seqirus, has developed the first sa-mRNA COVID-19 vaccine, Kostaive, in the world. The drug is currently approved in Japan and the EU.
This pharmaceutical company is expected to post quarterly loss of $1.09 per share in its upcoming report, which represents a year-over-year change of -319.2%. Revenues are expected to be $16.67 million, down 60% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Arcturus Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARCT going forward to see if this recent jump can turn into more strength down the road.
Arcturus Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Septerna, Inc. (SEPN - Free Report) , finished the last trading session 5% lower at $21.31. SEPN has returned 40.3% over the past month.
For Septerna, Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.19. This represents a change of +102.3% from what the company reported a year ago. Septerna, Inc. currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
Arcturus Therapeutics (ARCT - Free Report) shares ended the last trading session 7.7% higher at $23.16. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.3% gain over the past four weeks.
The sudden uptick can be attributed to a positive investor mindset regarding the potential of ARCT’s wholly-owned pipeline comprising two mRNA therapeutic candidates, ARCT-810 and ARCT-032, undergoing mid-stage development for ornithine transcarbamylase deficiency and cystic fibrosis, respectively. Arcturus, in partnership with renowned vaccine company CSL Seqirus, has developed the first sa-mRNA COVID-19 vaccine, Kostaive, in the world. The drug is currently approved in Japan and the EU.
This pharmaceutical company is expected to post quarterly loss of $1.09 per share in its upcoming report, which represents a year-over-year change of -319.2%. Revenues are expected to be $16.67 million, down 60% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Arcturus Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARCT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Arcturus Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Septerna, Inc. (SEPN - Free Report) , finished the last trading session 5% lower at $21.31. SEPN has returned 40.3% over the past month.
For Septerna, Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.19. This represents a change of +102.3% from what the company reported a year ago. Septerna, Inc. currently has a Zacks Rank of #3 (Hold).